Cancer vaccines, including DC vaccines, however, have been criticised for their low therapeutic efficacy, so it is thought that combining them with other immunomodulatory agents such as immune checkpoint inhibitors, IDO1 inhibitors, Ontak, and other intervention strategies may improve patient outcomes [269]. The gene discussed is IDO1; the disease is cancer.